Table 3.
Effect estimate for key outcomes within each treatment arm compared to baseline (pre to post comparisons)
| Cherry extract N (%) or mean (SD) (N = 41)† |
p-value | Diet modification N (%) or mean (SD) (N = 43)† |
p-value | |||
|---|---|---|---|---|---|---|
| Baseline | 9-month | Baseline | 9-month | |||
|
| ||||||
| Number of gout flares/month (patient-reported) * | 0.36 | 0.22 | 0.049 | 0.31 | 0.28 | 0.76 |
| Proportion with any gout flare (patient-reported) * | 40 (98%) | 23 (56%) | <0.0001 | 42 (98%) | 28 (65%) | 0.0002 |
| HAQ ** | 0.55 (0.68)1 | 0.28 (0.54) | 0.001 | 0.48 (0.61)2 | 0.23 (0.40) | 0.06 |
| Serum urate ** | 7.24 (1.98) | 7.16 (1.71) | 0.77 | 7.14 (1.99) | 7.00 (1.91) | 0.63 |
|
| ||||||
| Patients Reporting Taking ULT Medications at Baseline | ||||||
|
| ||||||
| N=13 | N=17 | |||||
|
| ||||||
| Number of gout flares/month (patient-reported) * | 0.57 | 0.21 | 0.04 | 0.30 | 0.19 | 0.18 |
| Proportion with any gout flare (patient-reported) * | 12 (92%) | 5 (38%) | 0.008 | 16 (94%) | 8 (47%) | 0.0047 |
| HAQ ** | 0.35 (0.42)3 | 0.18 (0.39) | 0.07 | 0.45 (0.28)4 | 0.23 (0.26) | 0.19 |
| Serum urate ** | 7.3 (1.7) | 7.3 (1.7) | 0.68 | 7.5 (1.9) | 7.7 (1.7) | 0.25 |
|
| ||||||
| Patients Reporting Not Taking ULT Medications at Baseline | ||||||
|
| ||||||
| N=27 | N=24 | |||||
|
| ||||||
| Number of gout flares/month (patient-reported) * | 0.27 | 0.23 | 0.42 | 0.28 | 0.33 | 0.61 |
| Proportion with any gout flare (patient-reported) * | 27 (100%) | 17 (63%) | NE | 24 (100%) | 20 (83%) | NE |
| HAQ ** | 0.61 (0.76)5 | 0.33 (0.60) | 0.01 | 0.49 (0.71)6 | 0.19 (0.43) | 0.08 |
| Serum urate ** | 7.0 (2.1) | 6.9 (1.7) | 0.84 | 6.9 (2.0) | 6.8 (2.0) | 0.64 |
NE, Not estimable; ULT, urate-lowering medication
Due to missing data, the denominators were smaller than the total sample, since these were for paired sample t-test:
N=32
N=26
N=9
N=7
N=22
N=18
There were three people with missing data for ULT use, therefore those with ULT (n=30) and without ULT at baseline (n=51) don’t add up to 84
Cumulative 9-month flares averaged to monthly gout flares during the study collected with 2-weekly gout flare questionnaire compared to average monthly baseline flares based on 12-month baseline report on patient recall (calculated by dividing baseline flares divided by 12)
Comparison of baseline to the 9-month study follow-up value
Bold represents significant p-value < 0.05